Sales and earnings by business segment

We expect further improvements in sales and earnings in 2010 in each of our business segments. The table gives an overview.

Financial Targets by Business Segment


  Targets 2010 Fiscal year 2009
1 Net income attributable to Fresenius Medical Care AG & Co. KGaA.
2 Sales
3 EBIT
Fresenius Medical Care    
Sales > US$ 12 billion US$ 11,247 million
Net income 1 US$ 950 – 980 million US$ 891 million
Fresenius Kabi    
Sales, growth (organic) 7 – 9 % € 3.086 million 2
EBIT margin 18 – 19 % 19.7 %
Fresenius Helios    
Sales, growth (organic) 3 – 5 % € 2.416 million 2
EBIT € 220 – 230 million € 205 million
Fresenius Vamed    
Sales, growth 5 – 10 % € 618 million 2
EBIT, growth 5 – 10 % € 36 million 3
Fresenius Biotech    
EBIT € - 35 − - 40 million € - 44 million

  Targets 2010 Fiscal year 2009
1 Net income attributable to Fresenius Medical Care AG & Co. KGaA.
2 Sales
3 EBIT
Fresenius Medical Care    
Sales > US$ 12 billion US$ 11,247 million
Net income 1 US$ 950 – 980 million US$ 891 million
Fresenius Kabi    
Sales, growth (organic) 7 – 9 % € 3.086 million 2
EBIT margin 18 – 19 % 19.7 %
Fresenius Helios    
Sales, growth (organic) 3 – 5 % € 2.416 million 2
EBIT € 220 – 230 million € 205 million
Fresenius Vamed    
Sales, growth 5 – 10 % € 618 million 2
EBIT, growth 5 – 10 % € 36 million 3
Fresenius Biotech    
EBIT € - 35 − - 40 million € - 44 million

The number of dialysis patients worldwide should rise by about 6 % in 2010, leading to continued growth in demand for dialysis products and a higher number of treatments. In 2010, Fresenius Medical Care expects to achieve revenue of more than US$ 12 billion. Net income is expected to be between US$ 950 million and US$ 980 million in 2010.

Fresenius Kabi expects its positive operating performance to continue in 2010. The company estimates organic sales growth of 7 to 9 % in constant currency. Good growth potential is expected again in the Asia-Pacific region and in Latin America. Based on the positive sales projection, further cost optimizations, especially in production, and an improved product mix, Fresenius Kabi again expects to increase earnings in 2010. Fresenius Kabi forecasts an EBIT margin of 18 to 19 %. Whilst still at an excellent level, the slightly reduced margin guidance reflects delayed IV drug market launches, lower Heparin product sales and the expectation of further increased price competition in the US IV generics market.

Fresenius Helios expects a continued good performance in the hospital operations business. The company forecasts an organic sales growth of 3 % to 5 % in 2010. EBIT is expected to increase to € 220 to 230 million.

Given its excellent order backlog of € 679 million and long-term agreements in its service business, Fresenius Vamed expects continued good performance in 2010. In 2010, Fresenius Vamed expects to achieve both sales and EBIT growth between 5 % and 10 %.

Fresenius Biotech will continue its targeted clinical study program, which will result in significant research and development expenditures. Although positive earnings contributions from the antibody Removab® that was launched on the market in 2009 will offset these expenditures for our biotechnology projects to some extent, we still expect negative EBIT between € -35 and € -40 million in 2010.

Continue reading:
Financing

QUICKFINDER